Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.
Ventorp F, Asp M, Olsson S, Lindahl J, Möller S, Svensson M, Ängeby F, Pravdinske A, Tjernberg J, Schrey S, Ståhl D, Magnusson V, Eliasson E, Agelii-Weber A, Stålhammar E, van Westen D, Deierborg T, Månsson KNT, Pizzagalli DA, Hammar Å, Tornberg ÅB, Björkstrand J, Lindqvist D
- DOI
- 10.1038/s41591-026-04465-9
- Record issued
- 2026-08-15
- Engine
- 7.39.0
- Exported
- 2026-09-21
Prepared by Alpha1. This document is confidential: it is intended for the recipient it was shared with and must not be redistributed. The live record at alpha1science.com/verify/d4b84291-b412-4cd1-b0a5-551179001bcf is authoritative.
How this rating was calculated
- IntegrityIntegrity concern ×2−1★
- ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
- ClaimsTreatment effect not shown to be clinically meaningful−0.5★
- 01Efficacy rests on an unvalidated surrogate endpoint
The primary outcome is the Snaith-Hamilton Pleasure Scale (SHAPS), a self-report questionnaire measuring anhedonia, which is a surrogate for clinical benefit. The paper does not provide evidence linking changes in SHAPS to hard clinical outcomes, nor does it demonstrate target engagement at the tested dose via PK/PD or dose-exposure relationships. Although fMRI and accelerometry are exploratory, the primary efficacy claim rests on a surrogate without a validated link to clinical outcomes.
“The primary outcome was change in SHAPS score from baseline to week 9.”
- 02Treatment effect not shown to be clinically meaningful
The primary effect size is a mean difference of -4.04 points on the SHAPS (Hedges' g = 0.62). While statistically significant, the paper does not anchor this change to a minimal clinically important difference (MCID) for SHAPS or to clinical meaningfulness. The effect is presented as a positive result without explicit justification that a 4-point change is clinically material.
“The difference in mean change was −4.04 (95% confidence interval: −6.89 to −1.18, P = 0.006, Hedges’ g = 0.62).”
This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.
This is a well-conducted and transparently reported randomized controlled trial of pramipexole for anhedonic depression. The design is rigorous, statistical reporting is strong, and data/code availability is exemplary. The main weakness is an incomplete ethics statement (specific committee name/approval number not given), plus minor reporting gaps such as insufficient power analysis detail and a minor blinding-integrity discrepancy.
Both reviewers classified the study as interventional (RCT), and I adopt that. The evaluation covered the full text, including methods, results, and supplementary references. Not applicable criteria (e.g., animal housing, cell line authentication) were excluded. The reviewers diverged slightly on power analysis adequacy (Reviewer 1 adequate, Reviewer 2 inadequate) and on the ethics statement (both inadequate), which I reconciled as a warn for ethics and a minor gap for power analysis.
Numerical inconsistencies
1 finding · worst lowValues that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.
- Internal contradictions in the reported numbersAssessed
Recomputed 4 tests: 4 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 3 via agent-written checks.
- CONSISTENTreported p < .050 · recomputed p = .031Recomputed z = −2.16, P < 0.05
“z = −2.16, P < 0.05”
Taken as given: the printed Z is a standard normal statistic — not a Kolmogorov–Smirnov, Wilcoxon or other rank-test Z that happens to be written the same way; the reported p is two-tailed, which is the convention where the paper does not say otherwise; the printed p is the p FOR THIS statistic, not for a different comparison reported nearbyMethod: recompute the two-tailed p from the printed z statistic and compare it against the printed pHow we recomputed it: pZ(-2.16) - CONSISTENTreported p = .006 · recomputed p = .006Reviewers 1, 2Primary outcome: difference in mean change in SHAPS between groups
“The difference in mean change was −4.04 (95% confidence interval: −6.89 to −1.18, P = 0.006, Hedges’ g = 0.62).”
Taken as given: The estimate is the mean difference (-4.04) and the 95% CI is (-6.89, -1.18).; The p-value is two-sided and derived from the confidence interval.Method: Recomputed two-sided p-value from the estimate and 95% CI using the normal approximation.How we recomputed it: pCI(-4.04, -6.89, -1.18, 0) - CONSISTENTreported p = .008 · recomputed p = .008Reviewers 1, 2Secondary outcome: DARS difference at week 9
“W9-BL | Pramipexole | 7.55 (1.82) | 3.96; 11.14 | | Placebo | 1.42 (1.40) | −1.34; 4.18 | 6.13 (2.29) | 1.60; 10.66 | 0.0083 | 0.59”
Taken as given: The estimate is the group difference (6.13) and the 95% CI is (1.60, 10.66).; The p-value is two-sided and derived from the confidence interval.Method: Recomputed two-sided p-value from the estimate and 95% CI using the normal approximation.How we recomputed it: pCI(6.13, 1.60, 10.66, 0) - CONSISTENTreported p < .001 · recomputed p = <.001Reviewers 1, 2Secondary outcome: AES-S difference at week 9
“W9-BL | Pramipexole | −7.92 (1.16) | −10.20; −5.63 | | Placebo | −2.94 (0.90) | −4.72; −1.16 | −4.97 (1.47) | −7.88; −2.07 | 0.0009 | −0.75”
Taken as given: The estimate is the group difference (-4.97) and the 95% CI is (-7.88, -2.07).; The p-value is two-sided and derived from the confidence interval.Method: Recomputed two-sided p-value from the estimate and 95% CI using the normal approximation.How we recomputed it: pCI(-4.97, -7.88, -2.07, 0)
- lowinternal contradictionThe abstract states 'Eighty-five participants were randomized, and 82 were included in the analysis.' The results section explains that two participants did not reach week 3 and one was ineligible, totaling three exclusions. This is consistent, but the text says 'Two participants did not reach week 3' and 'One participant ... met the eligibility criteria at screening but not at baseline' - that sums to three, which matches the difference between 85 and 82. No contradiction.
“Eighty-five participants were randomized, and 82 were included in the analysis.”
AbstractFind in source - lowinternal contradictionIn the blinding integrity section, the placebo group had 66.66% correct guesses, but the text says 'Among placebo recipients who guessed correctly ( n = 26)'. However, the placebo group had 41 participants, and 66.66% of 41 is approximately 27.3, not 26. This is a minor discrepancy, possibly due to rounding or missing data.
“However, in the placebo group, 66.66% correctly guessed that they were allocated to placebo, 20.51% guessed pramipexole and 12.82% were unsure.”
ResultsFind in source
Overstated conclusions
3 findings · worst highConclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.
- Efficacy rests on an unvalidated surrogate endpointAssessed
- Treatment effect not shown to be clinically meaningfulAssessed
- Conclusions only partially backed by the presented evidenceAssessed
7 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.
- partialReviewer 1Pramipexole was associated with increased light physical activity.The main effect of treatment on LPA was significant (P=0.0031), but the between-group difference at week 9 was not significant, and the authors note reduced compliance with accelerometer wear at the final week.Evidence: Exploratory outcomes section on LPA.
“Exploratory analyses indicated that pramipexole was associated with increased light physical activity”
AbstractFind in source - partialReviewer 2Pramipexole increased light physical activity.The main effect of treatment on LPA was significant (P=0.0031), but the between-group difference at week 9 was not significant. The claim is supported by the overall analysis but not by the endpoint comparison.Evidence: LPA analysis: significant main effect (P=0.0031), but pairwise at week 9 not significant.
“Consistent with our hypotheses, there was a significant main effect of treatment ( P = 0.0031) in the MMRM analysis, which included all 9 weeks of the RCT, indicating that pramipexole produced greater overall improvement in LPA delta scores compared to placebo.”
ResultsFind in source - supportedReviewers 1, 2Pramipexole significantly improved anhedonia compared to placebo.The primary outcome (SHAPS change) showed a significant difference favoring pramipexole, with a mean difference of -4.04 (95% CI -6.89 to -1.18, P=0.006).Evidence: Primary outcome analysis in Results section.
“Pramipexole significantly improved anhedonia and showed a favorable safety profile, supporting its potential as an augmentation strategy in mood disorders.”
AbstractFind in source - supportedReviewers 1, 2Pramipexole preserved reward-related ventral striatal activation.The fMRI substudy showed a significant group difference (P=0.030) favoring pramipexole in ventral striatal BOLD response.Evidence: Exploratory outcomes section on reward-related BOLD activity.
Exploratory analyses indicated that pramipexole was associated with ... relative preservation of reward-related ventral striatal activation.
Abstractreviewer’s wording - supportedReviewers 1, 2Improvements in anhedonia were sustained during a 6-month open-label extension.SHAPS scores continued to improve during the open-label phase, though this phase lacked a control group and is descriptive.Evidence: Results section on open-label extension.
“Improvements in anhedonia were sustained during a 6-month open-label extension.”
AbstractFind in source - supportedReviewer 1Pramipexole was generally well tolerated compared to placebo.No serious adverse events occurred during the RCT, and dropout rates were low, though specific side effects were more common with pramipexole.Evidence: Safety results section.
“Pramipexole was generally well tolerated compared to placebo.”
AbstractFind in source - supportedReviewer 2Pramipexole showed a favorable safety profile.No serious adverse events occurred during the RCT, and the dropout rate was low. Adverse events were more common with pramipexole but were mostly mild to moderate.Evidence: Safety results: no serious adverse events, low dropout, and manageable side effects.
“No serious adverse events occurred during the RCT phase. Pramipexole was generally well tolerated; one patient discontinued due to a suspected allergic reaction later assessed as unrelated to treatment.”
ResultsFind in source
Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.
- INADEQUATESurrogate endpointThe primary outcome is the Snaith-Hamilton Pleasure Scale (SHAPS), a self-report questionnaire measuring anhedonia, which is a surrogate for clinical benefit. The paper does not provide evidence linking changes in SHAPS to hard clinical outcomes, nor does it demonstrate target engagement at the tested dose via PK/PD or dose-exposure relationships. Although fMRI and accelerometry are exploratory, the primary efficacy claim rests on a surrogate without a validated link to clinical outcomes.
“The primary outcome was change in SHAPS score from baseline to week 9.”
- INADEQUATEEffect sizeThe primary effect size is a mean difference of -4.04 points on the SHAPS (Hedges' g = 0.62). While statistically significant, the paper does not anchor this change to a minimal clinically important difference (MCID) for SHAPS or to clinical meaningfulness. The effect is presented as a positive result without explicit justification that a 4-point change is clinically material.
“The difference in mean change was −4.04 (95% confidence interval: −6.89 to −1.18, P = 0.006, Hedges’ g = 0.62).”
Data authenticity concerns
None foundAn adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.
Checked — nothing surfaced.
Reporting gaps
None foundRequired detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.
Checked — nothing surfaced.
The introduction cites multiple prior studies on anhedonia, dopamine, and pramipexole, including a pilot study and a recent RCT. It acknowledges limitations of previous trials, such as insufficient dosing and heterogeneous populations, and explains how the current study addresses these (e.g., flexible dosing, transdiagnostic approach). The rationale linking dopamine agonism to anhedonia is well-articulated.
“A pilot study conducted by our group provided preliminary evidence suggesting an antianhedonic effect of pramipexole , which was partly supported by a recent RCT .”
“Together, these multimodal assessments were designed to provide a comprehensive evaluation of pramipexole’s clinical efficacy and mechanistic effects on anhedonia.”
Randomization was computer-generated with random block sizes (4-6), and allocation concealment was maintained. Blinding was double-blind with separate teams for RCT and open-label phases. A power analysis was conducted (though details are not fully reported in the text, the sample size was justified). Inclusion/exclusion criteria were pre-specified. The modified ITT population was defined. Outlier handling is addressed through the pre-specified analysis population and sensitivity analyses (LOCF).
“The block size varied randomly between 4 and 6, and the order within the blocks was generated randomly using a computer-based algorithm.”
“To maintain blinding in the RCT, a separate team of study physicians and nurses conducted the open-label extension phase.”
“Inclusion criteria were age 18–75 years; a current diagnosis of MDD, dysthymia or bipolar disorder with a depressive episode; ongoing treatment with at least one antidepressant or mood-stabilizing medication for ≥4 weeks; and a history of at least one adequate antidepressant trial without remission.”
“Patients, research physicians and nurses involved in patient assessments were blinded for treatment allocation.”
“Inclusion criteria were age 18–75 years; a current diagnosis of MDD, dysthymia or bipolar disorder with a depressive episode; ongoing treatment with at least one antidepressant or mood-stabilizing medication for ≥4 weeks; and a history of at least one adequate antidepressant trial without remission.”
The paper reports age, sex, BMI, and various clinical characteristics in Table 1. Both sexes are included, so sex_justified is not applicable. Age and health status are reported. Demographics are comprehensive for a human trial.
“Thirty-seven (45.12%) participants were female.”
“Age, mean (s.d.) | 47.44 (13.14) | 47.00 (14.32) | 47.22 (13.66)”
“Percent anxiety disorder | 39.02% ( n = 16) | 39.02% ( n = 16) | 39.02% ( n = 32)”
“Age, mean (s.d.) | 47.44 (13.14) | 47.00 (14.32) | 47.22 (13.66) | | Percent women (self-reported) | 46.34% ( n = 19) | 43.90% ( n = 18) | 45.12% ( n = 37)”
“Percent anxiety disorder | 39.02% ( n = 16) | 39.02% ( n = 16) | 39.02% ( n = 32)”
The paper states that all participants provided written informed consent. Although the specific ethics committee name is not in the provided text, the trial is registered on ClinicalTrials.gov and the protocol was published, implying ethical approval. The data availability statement mentions GDPR compliance and institutional ethics committee approval for data sharing, indicating ethical oversight.
“All participants provided written informed consent prior to study participation.”
“Deidentified participant data underlying the findings of this study will be made available from the corresponding author, subject to approval by the relevant institutional ethics committee and in accordance with GDPR and local data protection regulations.”
“All participants provided written informed consent prior to study participation.”
“Deidentified participant data underlying the findings of this study will be made available from the corresponding author, subject to approval by the relevant institutional ethics committee”
“ClinicalTrials.gov identifiers: NCT05355337 (http://clinicaltrials.gov/study/NCT05355337) and NCT05825235 (http://clinicaltrials.gov/study/NCT05825235) .”
Pramipexole is identified as extended-release tablets from STADA Nordic, and placebo from Ardena. The dose and regimen are described. Statistical software (SPSS, SAS, R) is identified with versions. No antibodies, cell lines, or other biological reagents are used, so those criteria are not applicable.
“Extended-release pramipexole tablets from STADA Nordic were labeled and repackaged consistent with European Union guidelines and Good Manufacturing Practice (GMP).”
“SPSS Statistics versions 28 and 30 (IBM Corporation), SAS Enterprise Guide 8.3 with SAS PROC MIXED and R (version 4.5.0) with the nlme (version 3.1-168) and emmeans (version 1.11.2-8) packages were used for statistical analysis.”
“Extended-release pramipexole tablets from STADA Nordic were labeled and repackaged consistent with European Union guidelines and Good Manufacturing Practice (GMP). Identical placebo tablets were produced by Ardena in line with GMP.”
“SPSS Statistics versions 28 and 30 (IBM Corporation), SAS Enterprise Guide 8.3 with SAS PROC MIXED and R (version 4.5.0) with the nlme (version 3.1-168) and emmeans (version 1.11.2-8) packages were used for statistical analysis.”
The primary analysis used a linear mixed model repeated measures (MMRM), which is appropriate. Tests are named (e.g., MMRM, chi-square, Fisher's r-to-z). Exact p-values are reported (e.g., P = 0.006). Effect sizes (Hedges' g) and 95% CIs are provided. Software is identified. Data presentation includes individual data points in figures and per-group n. Mathematical plausibility checks were not performed due to continuous outcomes and large N.
“The difference in mean change was −4.04 (95% confidence interval: −6.89 to −1.18, P = 0.006, Hedges’ g = 0.62).”
“The difference in mean change was −4.04 (95% confidence interval: −6.89 to −1.18, P = 0.006, Hedges’ g = 0.62).”
“SPSS Statistics versions 28 and 30 (IBM Corporation), SAS Enterprise Guide 8.3 with SAS PROC MIXED and R (version 4.5.0) with the nlme (version 3.1-168) and emmeans (version 1.11.2-8) packages were used for statistical analysis.”
“The difference in mean change was −4.04 (95% confidence interval: −6.89 to −1.18, P = 0.006, Hedges’ g = 0.62).”
“Non-parametric correlation analyses (Spearman) were conducted to examine associations between ventral striatal activation and SHAPS change scores. SPSS Statistics versions 28 and 30 (IBM Corporation), SAS Enterprise Guide 8.3 with SAS PROC MIXED and R (version 4.5.0) with the nlme (version 3.1-168) and emmeans (version 1.11.2-8) packages were used for statistical analysis.”
“Group means are represented by solid lines, with shaded ribbons indicating ±1 s.e.”
The data availability statement provides a clear mechanism for accessing deidentified data, subject to ethics approval and GDPR, with a timeframe. The statistical analysis code is publicly available on GitHub with a permanent identifier. The study protocol and SAP are available on ClinicalTrials.gov.
“Deidentified participant data underlying the findings of this study will be made available from the corresponding author, subject to approval by the relevant institutional ethics committee and in accordance with GDPR and local data protection regulations. Requests will be acknowledged within 2 weeks. After approval and completion of any required data-sharing agreements, data will typically be made available within 4–8 weeks.”
“The SAS syntax and R scripts used for the analyses in this study are publicly available under the MIT license at https://github.com/UnitforBAPP/PRIME-PRAXOL_RCT/”
“Deidentified participant data underlying the findings of this study will be made available from the corresponding author, subject to approval by the relevant institutional ethics committee and in accordance with GDPR and local data protection regulations. Requests will be acknowledged within 2 weeks. After approval and completion of any required data-sharing agreements, data will typically be made available within 4–8 weeks.”
“The SAS syntax and R scripts used for the analyses in this study are publicly available under the MIT license at https://github.com/UnitforBAPP/PRIME-PRAXOL_RCT/ (http://github.com/UnitforBAPP/PRIME-PRAXOL_RCT/) .”
The trial is registered on ClinicalTrials.gov with identifiers. A CONSORT checklist is mentioned in supplementary information. All outcomes are reported, including negative results. Limitations are thoroughly discussed. Conclusions are proportional to the evidence. Funding sources and competing interests are declared.
“Supplementary Information Supplementary Tables 1–5, Fig. 1, Data 1 and 2, study protocol, statistical analysis plan and CONSORT checklist.”
“Another limitation is that we did not adjust for multiplicity across secondary outcomes, increasing the risk of type I error and warranting cautious interpretation of these findings.”
“ClinicalTrials.gov identifiers: NCT05355337 (http://clinicaltrials.gov/study/NCT05355337) and NCT05825235 (http://clinicaltrials.gov/study/NCT05825235) .”
“Another limitation is that we did not adjust for multiplicity across secondary outcomes, increasing the risk of type I error and warranting cautious interpretation of these findings.”
Registered (4 IDs: ClinicalTrials.gov, EudraCT). Reporting guideline cited: CONSORT.
Broken references and links
None foundReferences checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.
Checked — nothing surfaced.
Checked 68 references by DOI: 63 verified — 5 no DOI (shown, not verified).
- NO DOIAnhedonia: Preclinical, Translational, and Clinical IntegrationNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIDelis−Kaplan Executive Function System (DKEFS)No DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIWechsler Adult Intelligence Scale (WAIS-IV): Technical and Interpretive ManualNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
- NO DOIThe Canadian Problem Gambling Index: Final ReportNo DOI in the reference — shown for manual review; not independently verifiable (not a fabrication signal).
4 data/code links checked; 4 live.
- datahttp://clinicaltrials.gov/study/NCT05355337LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- datahttp://clinicaltrials.gov/study/NCT05825235LIVEHTTP 200Resolves, but the content could not be matched to the paper.
- codeGitHubLIVEHTTP 200https://github.com/UnitforBAPP/PRIME-PRAXOL_RCT/Resolves to GitHub (code repository).
- codeGitHubLIVEHTTP 200http://github.com/UnitforBAPP/PRIME-PRAXOL_RCT/Resolves to GitHub (code repository).
Copyediting
4 minorWording, consistency and formatting errors that need correcting before submission.
No major wording or formatting errors. 4 minor suggestions below.
4 copyedit issues flagged: mostly consistency, other.
- MINORconsistencyAbstract“Pramipexole, in patients with major depressive disorder, dysthymia or bipolar depression, reduced Snaith−Hamilton Pleasure Scale scores significantly compared to placebo.”→ Consider rephrasing for clarity: 'Pramipexole significantly reduced Snaith-Hamilton Pleasure Scale scores compared to placebo in patients with major depressive disorder, dysthymia, or bipolar depression.'Awkward sentence structure.
- MINORconsistencyResults, Safety RCT phase“sleep disturbances (72.09% versus 33.33%)”→ Ensure percentages are consistent with denominators (e.g., 72.09% of 43 = 31, 33.33% of 42 = 14).Percentages appear plausible but should be verified.
- MINORotherData availability“Requests will be acknowledged within 2 weeks. After approval and completion of any required data-sharing agreements, data will typically be made available within 4–8 weeks.”→ Consider specifying the exact contact email or data access committee.Minor clarity improvement.
- MINORconsistencyResults, Safety RCT phase“sleep disturbances (72.09% versus 33.33%)”→ Ensure percentages are consistent with the number of participants (e.g., 72.09% of 43 = 31, but the text does not specify counts).Percentages are given without counts; consider adding counts for clarity.
The published work is robust and generally trustworthy, with strong design, statistical reporting, and transparency. An informed reader should weigh the minor reporting gaps (missing ethics committee name/approval number, limited power analysis detail, and a small blinding-integrity discrepancy) as non-fatal but worth noting. No erratum is warranted for these issues, but the authors could consider a correction to add the ethics approval details and clarify the blinding-integrity numbers.
- 1.HIGHethicsIn the Methods/Ethics section, explicitly name the institutional ethics committee (e.g., Swedish Ethical Review Authority) and provide the approval number.The current ethics statement is incomplete, which is a reporting gap that readers and journals expect to be filled.
- 2.HIGHreportingIn the Methods, provide the specific power analysis parameters (assumed effect size, alpha, power) used to determine the sample size.The text only references a pilot study; full documentation of the power analysis strengthens the sample size justification.
- 3.MEDIUMreportingIn the Results, clarify the blinding-integrity numbers: the text states 66.66% correct guesses in the placebo group but also reports n=26 correct guesses out of 41 participants, which is inconsistent (66.66% of 41 ≈ 27.3).This minor discrepancy could confuse readers and should be reconciled or explained.
- 4.MEDIUMreportingIn the Results, report the exact p-values for the chi-square tests on response and remission rates (currently reported as P ≥ 0.283 and P ≥ 0.655).Exact p-values improve precision and transparency.
- 5.MEDIUMreportingIn the Methods, clarify the exact definition of the modified intention-to-treat population, including how the three excluded participants were handled in sensitivity analyses.This clarifies the analysis population and enhances reproducibility.
- 6.MEDIUMreportingIn the Results, report the exact p-values for the blinding integrity test in the placebo group (P = 0.053) and the pramipexole group (P = 0.117) in the main text, as they are only in the supplementary.Blinding integrity is a key quality metric; reporting exact p-values in the main text improves transparency.
- 7.MEDIUMreportingIn the Methods, specify the version of the CONSORT checklist used and how it was followed.This enhances transparency regarding adherence to reporting guidelines.
- 8.MEDIUMreportingIn the Results, for the fMRI substudy, report the number of participants excluded for each reason.This improves transparency about missing data in the substudy.
- 9.MEDIUMreportingIn the Discussion, consider discussing the potential impact of the imbalance in SNRI use between groups on the primary outcome, even though post hoc analyses suggested no effect.Addressing this potential confounder strengthens the interpretation.
- 10.MEDIUMreportingIn the Methods, clarify the handling of missing data for the fMRI substudy and other exploratory outcomes, as the main analysis used MMRM but the substudy analyses may have used complete-case analysis.Clarifying missing data handling for all analyses improves reproducibility.
- 11.LOWcopyeditIn the Abstract, rephrase the sentence 'Pramipexole, in patients with major depressive disorder, dysthymia or bipolar depression, reduced Snaith−Hamilton Pleasure Scale scores significantly compared to placebo.' for clarity.The current sentence structure is awkward and could be misinterpreted.
- 12.LOWcopyeditIn the Results, Safety RCT phase, verify that the percentages for sleep disturbances (72.09% versus 33.33%) are consistent with the denominators (e.g., 72.09% of 43 = 31, 33.33% of 42 = 14) and consider adding counts.Ensuring percentage-count consistency avoids potential confusion.
- 13.LOWdata codeIn the Data Availability statement, consider specifying the exact contact email or data access committee to further clarify the access route.This minor addition would make the data access process more concrete.
The star rating is the report’s one-glance summary. Every paper starts at 5★ and loses stars for the concrete problems the review finds — so a rating is never a vague average, it’s a running total you can read line by line under “How this rating was calculated.”
- Reporting — 8 dimensionseach dimension that fully fails−½★
- each dimension partially met−¼★
- Statistics · Integrity · Claimseach serious problem−1★
- each medium problem−½★
- Citationseach retracted or unverifiable reference−¼★
- Copyeditonly when the manuscript needs a full edit−½★
The rating never drops below 1★, and a demonstrable critical failure (an impossible statistic, a proven ethics violation) caps it at 1★ on its own — so the stars can never look healthy when the verdict is CRITICAL.
The rating draws on a panel of agents. Three independent Kaimen Rigor reviewers grade the eight dimensions below across several independent passes (the shown verdict is their majority vote — steadier than any single run), isolate the paper’s major claims and check its own evidence backs them, and flag integrity concerns. Alongside them, a citation agent resolves every reference against Crossref, OpenAlex, and Retraction Watch; a statistics agent recomputes reported tests; and rule-based checks verify that declared data/code links actually resolve. Full text is required — an abstract-only submission is not analyzed.
Graded against NIH, MDAR, ARRIVE 2.0, CONSORT, EQUATOR, and RRID guidelines. A dimension that doesn’t apply to the study type is skipped, never penalized.
This Kaimen Rigor review is model-assisted and is not a substitute for formal expert review. It complements human evaluation by surfacing potential methodological concerns — verify each finding against the source.